StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note published on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of TTNP opened at $3.41 on Friday. The firm has a fifty day simple moving average of $3.57 and a two-hundred day simple moving average of $4.24. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- What Investors Need to Know to Beat the Market
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Basic Materials Stocks Investing
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
